Abstract
This minireiew summarizes recent new developments in visceral analgesics. This promising field is important, as a new approach to address abdominal pain with peripheral visceral analgesics is considered a key approach to addressing the current opioid crisis. Some of the novel compounds address peripheral pain mechanisms through modulation of opioid receptors via biased ligands, nociceptin/ orphanin FQ opioid peptide (NOP) receptor, or dual action on NOP and μ-opioid receptor, buprenorphine and morphiceptin analogs. Other compounds target nonopioid mechanisms, including cannabinoid (CB2), N-methyl-D-aspartate, calcitonin gene-related peptide, estrogen, and adenosine A2B receptors and transient receptor potential (TRP) channels (TRPV1, TRPV4, and TRPM8). Although current evidence is based predominantly on animal models of visceral pain, early human studies also support the evidence from the basic and animal research. This augurs well for the development of nonaddictive, visceral analgesics for treatment of chronic abdominal pain, an unmet clinical need.
| Original language | English (US) |
|---|---|
| Pages (from-to) | G637-G646 |
| Journal | American Journal of Physiology - Gastrointestinal and Liver Physiology |
| Volume | 314 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jun 1 2018 |
Fingerprint
Keywords
- Cannabinoid
- Estrogen
- Receptors
- Transient receptor potential
ASJC Scopus subject areas
- Physiology
- Hepatology
- Gastroenterology
- Physiology (medical)
Cite this
Toward an effective peripheral visceral analgesic : Responding to the national opioid crisis. / Camilleri, Michael.
In: American Journal of Physiology - Gastrointestinal and Liver Physiology, Vol. 314, No. 6, 01.06.2018, p. G637-G646.Research output: Contribution to journal › Short survey
}
TY - JOUR
T1 - Toward an effective peripheral visceral analgesic
T2 - Responding to the national opioid crisis
AU - Camilleri, Michael
PY - 2018/6/1
Y1 - 2018/6/1
N2 - This minireiew summarizes recent new developments in visceral analgesics. This promising field is important, as a new approach to address abdominal pain with peripheral visceral analgesics is considered a key approach to addressing the current opioid crisis. Some of the novel compounds address peripheral pain mechanisms through modulation of opioid receptors via biased ligands, nociceptin/ orphanin FQ opioid peptide (NOP) receptor, or dual action on NOP and μ-opioid receptor, buprenorphine and morphiceptin analogs. Other compounds target nonopioid mechanisms, including cannabinoid (CB2), N-methyl-D-aspartate, calcitonin gene-related peptide, estrogen, and adenosine A2B receptors and transient receptor potential (TRP) channels (TRPV1, TRPV4, and TRPM8). Although current evidence is based predominantly on animal models of visceral pain, early human studies also support the evidence from the basic and animal research. This augurs well for the development of nonaddictive, visceral analgesics for treatment of chronic abdominal pain, an unmet clinical need.
AB - This minireiew summarizes recent new developments in visceral analgesics. This promising field is important, as a new approach to address abdominal pain with peripheral visceral analgesics is considered a key approach to addressing the current opioid crisis. Some of the novel compounds address peripheral pain mechanisms through modulation of opioid receptors via biased ligands, nociceptin/ orphanin FQ opioid peptide (NOP) receptor, or dual action on NOP and μ-opioid receptor, buprenorphine and morphiceptin analogs. Other compounds target nonopioid mechanisms, including cannabinoid (CB2), N-methyl-D-aspartate, calcitonin gene-related peptide, estrogen, and adenosine A2B receptors and transient receptor potential (TRP) channels (TRPV1, TRPV4, and TRPM8). Although current evidence is based predominantly on animal models of visceral pain, early human studies also support the evidence from the basic and animal research. This augurs well for the development of nonaddictive, visceral analgesics for treatment of chronic abdominal pain, an unmet clinical need.
KW - Cannabinoid
KW - Estrogen
KW - Receptors
KW - Transient receptor potential
UR - http://www.scopus.com/inward/record.url?scp=85048218115&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048218115&partnerID=8YFLogxK
U2 - 10.1152/ajpgi.00013.2018
DO - 10.1152/ajpgi.00013.2018
M3 - Short survey
VL - 314
SP - G637-G646
JO - American Journal of Physiology - Gastrointestinal and Liver Physiology
JF - American Journal of Physiology - Gastrointestinal and Liver Physiology
SN - 0193-1857
IS - 6
ER -